temozolomide has been researched along with Uveal Neoplasms in 6 studies
Uveal Neoplasms: Tumors or cancer of the UVEA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This noncomparative phase II study evaluated a combination of bevacizumab (10 mg/kg on days 8 and 22) with temozolomide (150 mg/m(2) on days 1-7 and 15-21) in 36 patients with metastatic uveal melanoma (MUM)." | 7.83 | Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma. ( Asselain, B; Bidard, FC; Cassoux, N; Decaudin, D; Diallo, A; Etienne-Grimaldi, MC; Mariani, P; Piperno-Neumann, S; Plancher, C; Rodrigues, M; Servois, V, 2016) |
| "Uveal melanoma is refractory to chemotherapy." | 5.35 | Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo. ( Aldrich, W; Dombos, C; Triozzi, PL, 2008) |
| "This noncomparative phase II study evaluated a combination of bevacizumab (10 mg/kg on days 8 and 22) with temozolomide (150 mg/m(2) on days 1-7 and 15-21) in 36 patients with metastatic uveal melanoma (MUM)." | 3.83 | Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma. ( Asselain, B; Bidard, FC; Cassoux, N; Decaudin, D; Diallo, A; Etienne-Grimaldi, MC; Mariani, P; Piperno-Neumann, S; Plancher, C; Rodrigues, M; Servois, V, 2016) |
| "Compared with temozolomide chemotherapy, the MEK inhibitor selumetinib extended progression-free survival by nearly 9 weeks in patients with melanoma of the eye participating in a phase II trial, making it the first effective drug for the rare disease." | 3.79 | Selumetinib shows promise in metastatic uveal melanoma. ( , 2013) |
| " Pharmacologic characterization (chemosensitivity) was also done in four models using two drugs, temozolomide and fotemustine, currently used in the clinical management of uveal melanoma." | 3.76 | Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. ( Asselain, B; Barillot, E; Bessard, MA; Couturier, J; Dahmani, A; Decaudin, D; Desjardins, L; Donnadieu, MH; Gentien, D; Lantz, O; Laurent, C; Mariani, P; Némati, F; Péguillet, I; Piperno-Neumann, S; Plancher, C; Reyes, C; Robert, D; Roman-Roman, S; Sastre-Garau, X; Saule, S, 2010) |
| "Uveal melanoma is characterized by mutations in GNAQ and GNA11, resulting in mitogen-activated protein kinase pathway activation." | 2.79 | Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. ( Abramson, DH; Albertini, MR; Ambrosini, G; Ancell, K; Bluth, M; Carvajal, RD; Chapman, PB; Dickson, MA; Doyle, A; Erinjeri, J; Flynn, PJ; Gajewski, TF; Hedvat, C; Joshua, AM; Kudchadkar, RR; Lao, CD; Lawson, DH; Lewis, K; Linette, GP; Lutzky, J; Marr, B; Milhem, MM; Panageas, KS; Quevedo, JF; Sato, T; Schwartz, GK; Sosman, JA; Wolchok, JD, 2014) |
| "Uveal melanoma is refractory to chemotherapy." | 1.35 | Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo. ( Aldrich, W; Dombos, C; Triozzi, PL, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carvajal, RD | 1 |
| Sosman, JA | 1 |
| Quevedo, JF | 1 |
| Milhem, MM | 1 |
| Joshua, AM | 1 |
| Kudchadkar, RR | 1 |
| Linette, GP | 1 |
| Gajewski, TF | 1 |
| Lutzky, J | 1 |
| Lawson, DH | 1 |
| Lao, CD | 1 |
| Flynn, PJ | 1 |
| Albertini, MR | 1 |
| Sato, T | 1 |
| Lewis, K | 1 |
| Doyle, A | 1 |
| Ancell, K | 1 |
| Panageas, KS | 1 |
| Bluth, M | 1 |
| Hedvat, C | 1 |
| Erinjeri, J | 1 |
| Ambrosini, G | 1 |
| Marr, B | 1 |
| Abramson, DH | 1 |
| Dickson, MA | 1 |
| Wolchok, JD | 1 |
| Chapman, PB | 1 |
| Schwartz, GK | 1 |
| Piperno-Neumann, S | 2 |
| Diallo, A | 1 |
| Etienne-Grimaldi, MC | 1 |
| Bidard, FC | 1 |
| Rodrigues, M | 1 |
| Plancher, C | 2 |
| Mariani, P | 2 |
| Cassoux, N | 1 |
| Decaudin, D | 2 |
| Asselain, B | 2 |
| Servois, V | 1 |
| Triozzi, PL | 1 |
| Aldrich, W | 1 |
| Dombos, C | 1 |
| Némati, F | 1 |
| Sastre-Garau, X | 1 |
| Laurent, C | 1 |
| Couturier, J | 1 |
| Desjardins, L | 1 |
| Lantz, O | 1 |
| Robert, D | 1 |
| Péguillet, I | 1 |
| Donnadieu, MH | 1 |
| Dahmani, A | 1 |
| Bessard, MA | 1 |
| Gentien, D | 1 |
| Reyes, C | 1 |
| Saule, S | 1 |
| Barillot, E | 1 |
| Roman-Roman, S | 1 |
| Eich, M | 1 |
| Roos, WP | 1 |
| Dianov, GL | 1 |
| Digweed, M | 1 |
| Kaina, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma[NCT01143402] | Phase 2 | 120 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary analysis will be performed among the Gnaq/Gna11 mutant patients. A stratified logrank test will be performed stratified by mutation status, M stage, and number of prior systemic therapies for metastatic disease. Due to the potential for a large number of strata and small strata sizes, the standard asymptotic stratified logrank test will be verified for robustness utilizing a permutation reference distribution. (NCT01143402)
Timeframe: The time from randomization to death due to any cause, assessed up to 5 years
| Intervention | Months (Median) |
|---|---|
| Arm I (Temozolomide) | 9.1 |
| Arm II (Selumetinib) | 11.8 |
The primary analysis will be performed among the Gnaq/Gna11 mutant patients. A stratified logrank test will be performed stratified by mutation status, M stage, and number of prior systemic therapies for metastatic disease. Due to the potential for a large number of strata and small strata sizes, the standard asymptotic stratified logrank test will be verified for robustness utilizing a permutation reference distribution. (NCT01143402)
Timeframe: The time from randomization to the earlier date of objective disease progression per Response Evaluation Criteria In Solid Tumors (RECIST) criteria or death due to any cause in the absence of progression, assessed up to 5 years
| Intervention | weeks (Median) |
|---|---|
| Arm I (Temozolomide) | 7 |
| Arm II (Selumetinib) | 15.9 |
1 trial available for temozolomide and Uveal Neoplasms
| Article | Year |
|---|---|
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Dise | 2014 |
5 other studies available for temozolomide and Uveal Neoplasms
| Article | Year |
|---|---|
Selumetinib shows promise in metastatic uveal melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Clinical Trials, Phase II as Topic; | 2013 |
Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Disease-Free | 2016 |
Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Cell Line, Tumor; Cel | 2008 |
Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dacarbazine; Female; Gen | 2010 |
Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caspase 7; Cell Cycle Proteins; Cell Line, Transformed | 2010 |